权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Deciphering the Role of Reductive Stress in Non Small Cell Lung Cancer

解读还原应激在非小细胞肺癌中的作用

基本信息

批准号：
10540372
负责人：
Liron Bar-Peled
金额：
$ 37.66万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-12-13 至 2026-11-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10540372
关键词：
Antioxidants Applications Grants Aspartate Biochemical Biologic Characteristic Biological Assay Biological Markers Biology CRISPR screen Cancer Model Cancer Patient Cancer cell line Cell Proliferation Cells Chemicals Companions Complex Cysteine Dependence Drug Metabolic Detoxication Electron Transport Environment Enzymes Equilibrium Foundations Functional disorder Gene Deletion Generations Genes Genetic Genetic Transcription Genomics Goals Growth Homeostasis Impairment In Vitro Lead Maintenance Malignant Neoplasms Malignant neoplasm of lung Measures Mediating Metabolic Metabolic Pathway Metabolism Methods Mitochondria Modeling Modification Mutation Non-Small-Cell Lung Carcinoma Oncogenic Oxidation-Reduction Oxidative Stress Pathway interactions Patients Pharmacology Play Point Mutation Production Proliferating Proteins Proteomics Reactive Oxygen Species Regulation Research Respiration Role Series Signal Transduction Signal Transduction Pathway Signaling Protein Stress Supplementation Technology Testing Therapeutic Tumor Suppressor Proteins Work anti-cancer therapeutic biomarker identification cancer cell cancer therapy cancer type cell growth cohort efficacy evaluation efficacy testing experimental study functional genomics genome-wide in vivo insight lung cancer cell metabolomics mitochondrial metabolism mutant next generation novel novel therapeutic intervention pharmacologic potential biomarker protein function reconstitution response small molecule inhibitor synergism therapeutic development therapeutic evaluation transcription factor transcriptomics translational therapeutics tumor growth

项目摘要

Project Summary Control of the redox homeostasis is essential to cancer cell proliferation and requires the delicate maintenance of oxidative and reductive metabolic pathways. This equilibrium is controlled by signal transduction pathways and imbalances lead to redox stress that potently blocks cancer growth. Much work has focused on the role of oxidative stress in cancer proliferation, however, the converse– reductive stress and its impact on malignant cells is poorly understood. We have studied the role of redox control in cancer in the context of modification of proteinaceous cysteines by reactive oxygen species and the NRF2 transcription factor pathway. NRF2 functions as the master regulator of the cellular antioxidant response and promotes the expression of key metabolic and detoxification genes to generate a reductive environment and negate oxidative stress. NRF2 is activated in many cancers including ~30% of non small cell lung cancers (NSCLC) through mutation of its negative regulator KEAP1. While NRF2 has been extensively studied in KEAP1-mutant NSCLCs, we wondered what role this pathway plays in the proliferation of NSCLC cell lines which are wildtype (WT) for KEAP1. To this end, we pharmacologically activated NRF2 in 50+ NSCLC cell lines (WT for KEAP1) and measured their proliferation. Unexpectedly, we find that in ~16% of NSCLC cell lines, NRF2 activation results in a severe block in proliferation. A genome wide CRISPR screen identifies that genes involved in mitochondrial metabolism, mitochondrial fusion and the electron transport chain (ETC) are major sensitizers to NRF2 activation when lost and can function as companion biomarkers for NRF2-sensitivity. In line with the generation of reductive stress following NRF2 activation, key cysteines on enzymes involved in mitochondrial metabolism and mitochondrial fusion are reduced as determined by chemical proteomic platforms. To explain these surprising biological characteristics we propose the following hypothesis: NRF2 activation in a subset of NSCLC cell lines promotes an overly reductive environment that decreases the activity of key enzymes in mitochondrial metabolism and mitochondrial respiration and fusion. The inactivation of these pathways synergize to block cell growth. In this grant application, we build on our research surrounding NRF2 sensitization and mechanistically characterize the role of reductive stress in NSCLC proliferation. In this grant application, we will comprehensively define KEAP1-dependence by identifying NRF2 regulation of mitochondrial metabolism/fusion at the protein, cellular and organismal levels. The research proposed herein, takes full advantage of a series of recently conceived methods: chemical proteomics, genome-wide CRISPR screens and untargeted metabolomics, which have previously been deployed in isolation, to be used in an integrated manner to effectively dissect how protein reduction underlies protein malfunction and KEAP1-dependence. These studies will not only provide a comprehensive understanding of NRF2/KEAP1 biology but may also lay the foundation for developing translational therapeutics to benefit lung cancer patients with deregulated NRF2 signaling.

项目总结